Does protamine chloride neutralize low molecular weight heparin sufficiently?

Area of Science:

• Pharmacology
• Biochemistry
• Hematology

Background:

• Heparin and low molecular weight heparin (LMWH) are anticoagulants with different clinical profiles.
• Protamine chloride is used to reverse heparin's anticoagulant effects.
• The comparative efficacy of protamine chloride against conventional heparin and LMWH requires detailed investigation.

Purpose of the Study:

• To compare the in vitro efficacy of protamine chloride in neutralizing conventional heparin (porcine mucosa) and a specific LMWH (Kabi 2165).
• To assess the impact of protamine chloride on heparin-induced prolongation of activated partial thromboplastin time (aPTT) and inhibition of Factor Xa and thrombin.

Main Methods:

• In vitro study design.
• Assessment of protamine chloride's neutralizing effect on activated partial thromboplastin time (aPTT) prolongation.
• Clot-based assays to evaluate the inhibition of Factor Xa and thrombin.

Main Results:

• Protamine chloride neutralized 99% of conventional heparin's effect on aPTT versus 70% for LMWH.
• Neutralization of Factor Xa inhibition was 95% for conventional heparin and 55% for LMWH.
• Complete neutralization of thrombin inhibition was observed for both heparin types.

Conclusions:

• Conventional heparin is more effectively neutralized in vitro by protamine chloride compared to LMWH.
• Protamine chloride's effectiveness in reversing LMWH's anticoagulant activity is less pronounced in vitro.
• Further in vivo studies are warranted to confirm protamine chloride's efficacy in managing LMWH-induced bleeding.